# Petrelintide

Canonical source: https://retacompare.com/encyclopedia/petrelintide

Long-acting amylin / calcitonin receptor agonist for monotherapy or combination with GLP-1 RA.

Reference facts

Also known asZP-8396CategoryGLP-1 & MetabolicMechanism of actionLong-acting amylin / calcitonin receptor agonist for monotherapy or combination with GLP-1 RA.TargetsAMY1R, AMY3R, Calcitonin receptorIndications under research or approvedObesityRegulatory status (reference entry)Investigational (Phase 2)Half-life~7 daysSequence notesLong-acting amylin analog from Zealand Pharma with proprietary fatty-acid linker.Originator / sponsorZealand PharmaFirst reported2023
    Primary References

Petrelintide Phase 1b, Lancet D&E 2025


    Explore research articles about Petrelintide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Petrelintide Phase 1b, Lancet D&E 2025: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00099-3/fulltext